Photodynamic therapy using mono-L-aspartyl chlorin e6 for rabbit experimental hepatoma

Area of Science:

• Oncology
• Photochemistry
• Medical Imaging

Background:

• Photodynamic therapy (PDT) and photodynamic diagnosis (PDD) are not yet clinically used for hepatoma.
• Mono-L-aspartyl chlorin e6 (MCE6) is a second-generation photosensitizer with high tumor affinity, enabling rapid detection without light-shielding.

Purpose of the Study:

• To investigate the potential of PDT using MCE6 for hepatoma treatment in a rabbit model.
• To evaluate the efficacy of MCE6-PDT in suppressing tumor growth, inducing necrosis, and preventing metastasis.

Main Methods:

• VX2 tumor cells were implanted in rabbit livers. Animals received MCE6 (2.5 mg/kg).
• Tumor accumulation of MCE6 was monitored. PDT was administered using a diode laser at varying intervals post-administration.
• Tumor growth, necrosis rates, and pulmonary metastasis were assessed. Liver function was monitored.

Main Results:

• MCE6 demonstrated accumulation in hepatoma.
• PDT was significantly more effective when irradiation occurred 5 minutes post-MCE6 administration compared to later intervals.
• Tumor growth suppression, increased necrosis, and reduced pulmonary metastasis were observed with early irradiation. No significant liver dysfunction was noted.

Conclusions:

• Photodynamic therapy with mono-L-aspartyl chlorin e6 is a potentially effective treatment for hepatoma.
• Optimal efficacy is achieved with early irradiation following photosensitizer administration.
• MCE6-PDT shows promise for clinical application in hepatoma therapy with a favorable safety profile.